AstraZeneca gets $1bn from US BARDA to support Covid-19 vaccine

21 May 2020 (Last Updated May 21st, 2020 10:55)

UK-based pharmaceutical company AstraZeneca has received more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) to develop, manufacture and deliver a Covid-19 vaccine developed by the University of Oxford.

Last month, AstraZeneca signed an agreement with the University of Oxford to develop and distribute the university’s Covid-19 vaccine candidate, ChAdOx1 nCoV-19.

The company has now finalised its licence agreement for the recombinant adenovirus vaccine, renamed AZD1222. In addition, the company has committed to supporting the formation of a joint research centre at Oxford University focused on pandemic preparedness research.